NIP
TERN

Nicholas Investment Partners’s Terns Pharmaceuticals TERN Stock Holding History

Nicholas Investment Partners’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.33M Sell
25,147
-140,634
-85% -$5.78M 0.1% 167
2025
Q4 		$6.7M Buy
+165,781
New +$3.83M 0.49% 76

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Nicholas Investment Partners's TERN Position: Q1 2026 in Review

Nicholas Investment Partners reduced its Terns Pharmaceuticals (TERN) stake by 85% in Q1 2026, selling an estimated $5.78M and leaving 25,147 shares worth $1.33M. The position accounts for 0.1% of the portfolio, ranked #167.

Nicholas Investment Partners first reported a position in TERN in Q4 2025 and has held it in 2 quarters since. The position peaked at $6.7M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Nicholas Investment Partners held 25,147 shares of Terns Pharmaceuticals worth $1.33M as of Q1 2026.
  • Nicholas Investment Partners sold 140,634 Terns Pharmaceuticals shares in Q1 2026, an estimated $5.78M.
  • Terns Pharmaceuticals made up 0.1% of Nicholas Investment Partners's portfolio in Q1 2026, its #167 holding.
  • Nicholas Investment Partners first reported a position in Terns Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Nicholas Investment Partners's Terns Pharmaceuticals position peaked at $6.7M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Nicholas Investment Partners's 13F filing for Q1 2026, filed 15 May 2026.